Marfan Syndrome — Cardiovascular Manifestations

Key Mechanism 1: Fibrillin-1 Deficiency and Microfibrillogenesis

• FBN1 gene mutations lead to abnormal fibrillin-1 protein synthesis or function, disrupting the normal assembly of extracellular microfibrils
• Microfibrils serve as scaffolding for elastic fiber formation and provide crucial structural integrity to blood vessel walls
• Defective microfibrils result in weakened structural support in the media layer of large elastic arteries, particularly the ascending aorta
• This leads to characteristic progressive dilatation and cystic medial necrosis (degeneration of elastic fibers with smooth muscle cell apoptosis)

Key Mechanism 2: Transforming Growth Factor-Beta (TGF-β) Dysregulation

• Fibrillin-1 normally binds and sequesters latent TGF-β complexes within the extracellular matrix
• Reduced fibrillin-1 levels result in excessive liberation and activation of TGF-β signaling pathways
• Unopposed TGF-β signaling promotes:
• Smooth muscle cell apoptosis and dedifferentiation
• Increased matrix metalloproteinase (MMP) activity
• Enhanced extracellular matrix degradation
• Myofibroblast activation in valve tissue
• This TGF-β-mediated mechanism explains why losartan (an angiotensin II receptor blocker that modulates TGF-β signaling) has therapeutic benefit beyond blood pressure reduction

Key Mechanism 3: Progressive Aortic Root Dilatation and Mechanical Failure

• The ascending aortic root (proximal to sinotubular junction) bears the greatest hemodynamic stress
• Weakened media with loss of elastic fibers cannot adequately resist systolic stress
• Progressive dilatation follows a sigmoidal curve, accelerating with increasing aortic diameter
• Pathologic dilatation leads to:
• Aortic regurgitation (AR) from commissural widening and valve cusp malcoaptation
• Annuloaortic ectasia with subsequent aortic valve incompetence
• Progressive wall stress (Laplace's law: wall stress = pressure × radius ÷ 2 × wall thickness)
• Risk of acute aortic dissection when diameter exceeds critical threshold (typically >5.0 cm, but varies by individual factors)

Major Cause 1: FBN1 Gene Mutations

• Autosomal dominant inheritance pattern with variable expressivity
• De novo mutations account for approximately 25% of cases
• Over 3,000 mutations identified, distributed throughout the gene
• Most mutations are nonsense, frameshift, or missense mutations affecting fibrillin-1 function
• Specific mutation types correlate with disease severity (neonatal lethal variants vs. mild skeletal manifestations with minimal cardiovascular involvement)
• Genotype-phenotype correlation remains imperfect; same mutation can produce variable cardiovascular phenotypes

Major Cause 2: Risk Factors Modifying Cardiovascular Manifestations

• Family history of aortic dissection or sudden cardiac death — indicates high-risk genotype
• Male sex — males demonstrate faster rates of aortic root dilatation (approximately 2-fold greater risk of dissection)
• Pregnancy — significant hemodynamic stress increases dissection risk in women (1-2% risk during pregnancy/postpartum in untreated cases with aortic root >5.5 cm)
• Systemic hypertension — accelerates aortic dilatation through increased hemodynamic load
• Aortic root diameter — strongest predictor of dissection risk; diameter >5.0-5.5 cm carries substantially increased risk
• Homozygosity or compound heterozygosity — extremely rare but associated with more severe phenotype

Cardinal Symptom 1: Palpitations and Syncope

• Often related to arrhythmias (atrial fibrillation, ectopy) or hemodynamic consequences of aortic regurgitation
• Syncope may indicate sudden increase in aortic regurgitation severity or arrhythmia
• Exertional chest pain — may precede aortic dissection or reflect pulmonary hypertension from chronic aortic regurgitation
• Dyspnea — secondary to aortic regurgitation causing left ventricular (LV) volume overload and heart failure or pulmonary edema

Cardinal Symptom 2: Acute Chest or Back Pain

• Sudden-onset, severe, tearing pain radiating to back/flank — pathognomonic for acute aortic dissection
• Often accompanied by diaphoresis, anxiety, and sense of impending doom
• Acute dissection represents true medical emergency with high mortality (1% mortality per hour if untreated)

Physical Examination Finding 1: Aortic Regurgitation Murmur

• Diastolic decrescendo murmur best heard at left sternal border with patient leaning forward
• Early diastolic timing reflects high-pressure gradient from dilated aortic root
• Severity increases with progressive aortic root dilatation
• Associated with wide pulse pressure, bounding pulses, and waterhammer appearance
• Austin Flint murmur (mid-to-late diastolic, low-pitched rumble at apex) indicates hemodynamically significant AR with forceful mitral valve closure from regurgitant jet

Physical Examination Finding 2: Skeletal Features and Arachnodactyly

• Arachnodactyly — disproportionately long, slender fingers and toes with reduced hand grip strength
• Positive wrist sign — thumb and fifth finger overlap when hand grasped around wrist (high sensitivity for Marfan syndrome)
• Positive thumb sign — thumb protrudes beyond palm edge when fingers flexed
• Tall stature with increased arm span-to-height ratio (>1.05)
• Pectus deformities — pectus carinatum or excavatum may alter cardiac position and predispose to mitral valve prolapse
• High-arched palate, dental crowding

Physical Examination Finding 3: Ocular and Other Connective Tissue Stigmata

• Ectopia lentis — upward lens subluxation (superior and temporal displacement)
• Severe myopia with refractive error
• Skin striae (especially over shoulders, buttocks)
• Joint hypermobility and skin hyperextensibility (less prominent than in Ehlers-Danlos syndrome)

Diagnostic Test 1: Transthoracic Echocardiography (TTE)

Interpretation

• Gold standard for initial cardiovascular screening and ongoing monitoring
• Measures aortic root diameter at sinuses of Valsalva (most critical measurement for prognosis and surgical planning)
• Aortic root >2 standard deviations above predicted normal (adjusted for age, sex, body surface area) is abnormal and warrants further evaluation
• Aortic regurgitation assessment — severity graded by jet width, regurgitant volume, and color-flow mapping
• Mitral valve prolapse — posterior displacement of mitral leaflets >2 mm above mitral annular plane in parasternal long axis
• Left ventricular dysfunction assessment — ejection fraction, wall motion, cavity dimensions (secondary to chronic AR)
• Frequency of monitoring:
• Every 6-12 months if aortic root >5.0 cm or rapidly progressive
• Annually for stable disease with moderate dilatation
• Every 2-3 years if minimal dilatation and no AR

Diagnostic Test 2: Transesophageal Echocardiography (TEE)

• Superior resolution for aortic root anatomy and aortic valve commissures
• Indicated when TTE image quality inadequate or when assessing for complications
• Better assessment of aortic arch involvement and descending thoracic aorta
• Essential in acute suspected aortic dissection (sensitivity 95-98% for dissection flap)

Diagnostic Test 3: Cardiac MRI

• High sensitivity and specificity for aortic root and ascending aorta dimensions
• Preferred modality for aortic arch and descending thoracic aorta evaluation
• Excellent for follow-up imaging to minimize radiation exposure
• Provides tissue characterization (cystic medial necrosis appearance)
• More reproducible measurements than echocardiography for research and close monitoring
• Longer acquisition times and contraindications (pacemakers) limit utility in acute settings

Diagnostic Test 4: Cardiac CT with Contrast

• Rapid acquisition makes it ideal for acute aortic dissection evaluation
• Superior spatial resolution compared to MRI for small differences in aortic diameter
• CT angiography of choice for acute dissection in hemodynamically unstable patients
• Involves radiation exposure; generally reserved for acute presentations

Diagnostic Test 5: Chest X-Ray

• May show widened mediastinum if aortic root severely dilated
• Can demonstrate pectus deformity
• Limited sensitivity and specificity; not adequate for diagnosis or monitoring

Lab Values and Genetic Testing

• No specific serum biomarkers reliably diagnose Marfan syndrome or predict cardiovascular outcomes
• FBN1 genetic testing — identifies pathogenic mutations; sensitivity 97% for clinically diagnosed individuals
• Genetic counseling recommended for all patients and families
• Skeletal surveys and ophthalmologic examination support clinical diagnosis but are not diagnostic alone

Diagnostic Criteria: Revised Ghent Nosology (2010)

Diagnosis requires

• Ectopia lentis (upward, not downward — downward suggests homocystinuria) PLUS systemic score ≥7 points, OR
• Aortic root dilatation (Z-score >2.0 adjusted for age/BSA) PLUS systemic score ≥7 points, OR
• FBN1 mutation PLUS either ectopia lentis OR aortic root dilatation (Z-score >2.0), OR
• Aortic root dilatation AND family history of Marfan syndrome

Systemic score ≥7 points from

• Skeletal features (pectus, arachnodactyly, wrist/thumb signs, tall stature, scoliosis, etc.) = 1-5 points
• Ocular features (myopia, ectopia lentis) = 1-2 points
• Skin/lung features (striae, hyperextensibility, spontaneous pneumothorax) = 1-2 points
• Family history = 1 point
• Cardiovascular features beyond aortic root dilatation = 1 point

First-Line Pharmacotherapy: Beta-Blockers

• Propranolol or atenolol — dosing titrated to heart rate <60 bpm at rest and <100 bpm with light exercise
• Evidence base: Landmark clinical trial demonstrated slowing of aortic root dilatation progression
• Effective for rate control and symptom management
• Generally well-tolerated; contraindications include decompensated heart failure or bradycardia
• Reduces dissection risk by 10-fold when combined with surgical intervention at appropriate diameter threshold

Second-Line Pharmacotherapy: Angiotensin II Receptor Blockers (ARBs)

• Losartan — initial dose 50 mg daily, titrated to target (typical 50-100 mg daily)
• Evidence suggests superior or equivalent efficacy to beta-blockers for slowing aortic root dilatation
• Combination therapy (losartan + beta-blocker) may provide additive benefit
• Recent studies support use as alternative first-line agent or in combination regimen
• Well-tolerated with renal monitoring for hyperkalemia and renal function
• Alternative ARBs (valsartan, irbesartan) likely provide similar benefit, though losartan has most supporting data

Third-Line Therapy: ACE Inhibitors

• Enalapril or other ACE inhibitors — provide TGF-β modulation similar to ARBs
• Evidence base less robust than losartan but reasonable alternative
• Some studies suggest inferior efficacy compared to ARBs and beta-blockers
• Generally reserved for patients intolerant to ARBs or beta-blockers

Emerging Therapy: Selective TGF-β Pathway Inhibitors

• Miglustat — iminosugar compound targeting TGF-β signaling; results from recent clinical trials pending
• Fibrillin-targeting therapies — investigational agents aimed at correcting fibrillin-1 function or reducing pathogenic fibrillin-1 variants

Management of Aortic Regurgitation

• Vasodilators (losartan, hydralazine) — reduce afterload and aortic pressure, decreasing severity of regurgitant jet
• Diuretics (furosemide, spironolactone) — manage volume overload and heart failure symptoms from chronic AR
• ACE inhibitors/ARBs — reduce LV remodeling from chronic volume overload
• Beta-blockers — reduce contractility and shorten LV ejection time, decreasing regurgitant volume
• Avoid arterial vasodilators that reflexively increase inotropy (direct-acting vasodilators with sympathomimetic properties)

Non-Pharmacological Measures

• Lifestyle modifications:
• Strenuous isometric exercise restriction (weightlifting, Valsalva maneuvers, contact sports)
• Encourage aerobic activities (walking, swimming, cycling) — cardiovascular conditioning without extreme hemodynamic stress
• Avoid stimulants (cocaine, decongestants) that increase contractility and aortic wall stress
• Blood pressure control to <130/80 mmHg (lower targets for those with aortic root dilatation)

• Surgical prophylaxis:
• Elective aortic root replacement (Bentall procedure with composite graft or valve-sparing root replacement) indicated when:
• Aortic root diameter ≥5.0 cm (or ≥4.7-4.8 cm if additional risk factors: male sex, family history of dissection, planned pregnancy, rapidly progressive dilatation)
• Aortic root diameter ≥5.5 cm with aortic regurgitation ≥moderate severity
• Earlier surgery (≥4.5 cm) considered with:
• Aortic dissection family history
• Planned pregnancy (elevated peripartum risk)
• Severe aortic regurgitation
• Rapidly progressive aortic dilatation (>5 mm/year)

• Obstetric counseling:
• Aortic root <4.0 cm: minimal risk; vaginal delivery acceptable
• Aortic root 4.0-5.0 cm: elective cesarean section recommended
• Aortic root >5.0 cm: pregnancy contraindicated without surgical repair

Monitoring and Follow-Up

• TTE every 6-12 months if aortic root ≥5.0 cm or rapidly progressive
• TTE annually for stable moderate dilatation (4.5-5.0 cm)
• TTE every 2-3 years if minimal dilatation (<4.5 cm) and normal aortic regurgitation
• MRI for more precise measurements when surgical decision-making critical
• Family screening — all first-degree relatives of affected individuals should undergo clinical evaluation, echocardiography, and ophthalmologic examination
• Genetic counseling for family planning

Emergencies — recognize immediately

• Acute type A aortic dissection: intimal tear in the medially degenerated ascending aorta; sudden tearing chest pain radiating to the back, pulse or blood-pressure differential between arms, new diastolic murmur, or focal neurologic deficit. The ACC/AHA 2022 Aortic Disease Guideline calls type A dissection an emergent surgical indication; stable patients get CT angiography, unstable patients get bedside TEE. Medical bridge is an IV beta blocker (esmolol) before any vasodilator (nitroprusside) — vasodilating first causes reflex tachycardia and raises dP/dt, propagating the flap.
• Cardiac tamponade / aortic rupture: retrograde dissection into the pericardium; hypotension, JVD, muffled heart sounds, pulsus paradoxus. Pericardiocentesis is generally avoided in favor of emergent operative decompression.
• Acute severe aortic regurgitation: commissural disruption by the dissection flap; flash pulmonary edema with a soft, short diastolic murmur and no wide pulse pressure — the murmur is quiet precisely because diastolic equalization occurs fast.
• Chordal rupture in mitral valve prolapse: abrupt severe mitral regurgitation with flail leaflet and pulmonary edema.
• Spontaneous pneumothorax from apical bleb rupture; sudden dyspnea and unilateral absent breath sounds.

Chronic and treatment-related

• Chronic AR with LV volume overload: progressive dilation, eccentric hypertrophy, and eventual systolic dysfunction; falling ejection fraction or rising LV end-systolic dimension on surveillance echo triggers surgery per the ACC/AHA 2020 Valvular Heart Disease Guideline.
• Arrhythmia and sudden death: atrial fibrillation from left atrial dilation; ventricular arrhythmia in advanced myopathic/MVP disease.
• Post-Bentall complications: mechanical prosthesis mandates lifelong warfarin (ACC/AHA 2020 VHD) with bleeding and valve-thrombosis risk; prosthetic valve endocarditis warrants dental antibiotic prophylaxis, which isolated MVP does not.
• Residual distal aortic disease: root replacement does not protect the arch or descending aorta — lifelong imaging surveillance is required.
• Drug toxicity: beta blockers cause bradycardia, fatigue, bronchospasm; ARBs cause hyperkalemia and AKI and are teratogenic, so losartan must be stopped before conception.

• **Tall, arachnodactyly, upward lens dislocation**: superotemporal ectopia lentis plus a diastolic murmur is Marfan (FBN1, fibrillin-1, TGF-β excess). Downward/inferonasal lens dislocation with thrombosis, marfanoid habitus, and intellectual disability is homocystinuria (cystathionine beta-synthase deficiency) — the single most tested look-alike.
• Single best next step for a newly suspected case: transthoracic echocardiography to measure the aortic root at the sinuses of Valsalva and calculate a Z-score. Genetic testing supports but does not replace the revised Ghent nosology.
• Single best next step for tearing chest pain: CT angiography if hemodynamically stable, TEE if unstable — and give the IV beta blocker before the vasodilator. Never anticoagulate or thrombolyse this patient for presumed ACS.
• The association examiners love: losartan works through TGF-β antagonism, not just afterload reduction — this is why an ARB is used in a normotensive Marfan patient.
• Pregnancy pearl: losartan and all ACE inhibitors are contraindicated in pregnancy; switch to a beta blocker (labetalol or metoprolol) preconception. Pregnancy is the highest-risk period for dissection, and the ACC/AHA 2022 Aortic Disease Guideline supports prepregnancy root replacement at lower diameter thresholds.
• Differentiate the connective tissue mimics: Loeys-Dietz (TGFBR1/2) shows hypertelorism, bifid uvula, and arterial tortuosity and dissects at smaller aortic diameters; vascular Ehlers-Danlos (COL3A1) causes hollow-organ and medium-vessel rupture with thin translucent skin and no ectopia lentis.
• Common distractor: a mid-systolic click with a late systolic murmur is mitral valve prolapse, which moves earlier with standing/Valsalva (decreased preload) and later with squatting or handgrip — do not confuse this with hypertrophic cardiomyopathy, where handgrip softens the murmur.
• Do not withhold beta blockade for fear of "masking" symptoms; rate and dP/dt control is the cornerstone of aortic protection.